RxDoctor Payments Data

Mohammad Rahman, MD

Internal Medicine · Macon, GANPI 1063515815

Payments from drug & device makers

$533in general payments, 2019–2025

Across 32 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$195
  • Astellas Pharma US Inc$150
  • GSK$61
  • Philips North America LLC$34
  • Boston Scientific$24
  • Novo Nordisk$22
  • plus $46 from 3 others

What the payments were for

  • Food & beverage$44884%
  • Education$8516%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$533 in reported general payments places this provider in the 55th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$68,517
Medicare patients
98
Services billed
971

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$110,334
JardianceEmpagliflozin85$97,909
OzempicSemaglutide64$81,007
TrulicityDulaglutide45$78,387
JanuviaSitagliptin Phosphate78$53,699
EntrestoSacubitril/Valsartan39$44,646
SymbicortBudesonide/Formoterol Fumarate59$24,257
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog23$21,730
XareltoRivaroxaban14$19,607
MyrbetriqMirabegron18$18,025
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$16,923
Spiriva RespimatTiotropium Bromide22$14,630
LevemirInsulin Detemir36$8,739
Atorvastatin Calcium986$6,729
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen330$6,229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$110,334130 claims
Novo NordiskOzempic, Levemir$22$89,746100 claims
NovartisEntresto$15$44,64639 claims
AstraZenecaSymbicort$195$24,25759 claims
GSKTrelegy Ellipta, Incruse Ellipta$61$20,13227 claims
Astellas Pharma US IncMyrbetriq$150$18,02518 claims
Sanofi-aventis U.S. LLCLantus$16$2,68129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →